1. Hospital-acquired bloodstream infections (HA-BSI) are associated with significant mortality in critically ill patients.
2. This study found that the most frequent sources of infection were pneumonia and intravascular catheters, and the most frequent pathogens were Gram-negative bacteria, predominantly Klebsiella spp., Acinetobacter spp., Escherichia coli, and Pseudomonas spp.
3. Mortality was high at 37%, and only 16% of patients had been discharged alive from hospital by day 28.
The article is a prospective international cohort study of adult patients with HA-BSI treated in intensive care units between June 2019 and February 2021. The article is well written and provides detailed information on the epidemiology and outcomes of hospital-acquired bloodstream infections in ICU patients. The authors have provided sufficient evidence to support their claims, including data from 333 ICUs in 52 countries, as well as data on patient characteristics, sources of infection, pathogens, antimicrobial resistance, delays to adequate antimicrobial therapy, source control measures, mortality rates, and discharge rates.
The article does not appear to be biased or one-sided; it presents both sides equally by providing detailed information on the epidemiology of HA-BSI as well as its associated risks and outcomes. It also provides insights into potential modifiable factors that could improve patient management and outcomes. Furthermore, the authors have noted possible risks associated with HA-BSI such as delays to adequate antimicrobial therapy due to antimicrobial resistance.
In conclusion, this article is trustworthy and reliable; it provides detailed information on the epidemiology and outcomes of hospital-acquired bloodstream infections in ICU patients without any bias or one-sided reporting.